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Abstract
Background: Delirium is common, distressing and associated with poor outcomes. Previous studies investigating the impact
of delirium on cognitive outcomes have been limited by incomplete ascertainment of baseline cognition or lack of prospective
delirium assessments. This study quantified the association between delirium and cognitive function over time by prospectively
ascertaining delirium in a cohort aged ≥ 65 years in whom baseline cognition had previously been established.
Methods: For 12 months, we assessed participants from the Cognitive Function and Ageing Study II-Newcastle for delirium
daily during hospital admissions. At 1-year, we assessed cognitive decline and dementia in those with and without delirium.
We evaluated the effect of delirium (including its duration and number of episodes) on cognitive function over time,
independently of baseline cognition and illness severity.
Results: Eighty two of 205 participants recruited developed delirium in hospital (40%). One-year outcome data were available
for 173 participants: 18 had a new dementia diagnosis, 38 had died. Delirium was associated with cognitive decline (−1.8
Mini-Mental State Examination points [95% CI –3.5 to –0.2]) and an increased risk of new dementia diagnosis at follow
up (OR 8.8 [95% CI 1.9–41.4]). More than one episode and more days with delirium (>5 days) were associated with worse
cognitive outcomes.
Conclusions: Delirium increases risk of future cognitive decline and dementia, independent of illness severity and baseline
cognition, with more episodes associated with worse cognitive outcomes. Given that delirium has been shown to be
preventable in some cases, we propose that delirium is a potentially modifiable risk factor for dementia.
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Key points
• Delirium increases risk of future cognitive decline.
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• Delirium may be a potentially modifiable risk factor for dementia.
Background
Delirium is a sudden onset and fluctuating cognitive disor-
der, frequently precipitated by acute illness, which specifi-
cally affects attention and level of arousal. Delirium is highly
distressing and common, affecting 1 in 4 older people in
hospital [1,2]. Delirium is independently associated with
increased institutionalisation and mortality, longer lengths
of hospital stay and more hospital-acquired complications,
culminating in substantial additional healthcare costs [2–4].
Delirium is a strong predictor of new-onset dementia as well
as acceleration of existing cognitive decline [5–7].
The degree to which delirium is associated with per-
manent changes in cognition is unclear because most
studies (outside specific elective surgical settings) have
not assessed prior cognitive function [8–10]. In contrast,
the studies that have ascertained prior cognitive function
lack reliable delirium measures [11–13]. Therefore, the
degree to which baseline cognition and delirium separately
or together contribute to cognitive outcomes remains
unknown. A further mediator may be acute hospitalisation
itself. This has been shown to adversely affect trajectories
of cognitive decline, even when delirium has not been
specifically ascertained [14–16]. This implies that delirium
and/or its acute causes can contribute to the overall burden
of dementia.
In order to address the relative contribution of acute and
chronic factors in determining subsequent cognitive impair-
ment, the Delirium and Cognitive Impact in Dementia
(DECIDE) study aimed to measure the effect of delirium on
cognition, independent of illness severity, in a population-
based cohort study of incident dementia. A further objective
was to quantify the association of other features of delirium,




The DECIDE study is a prospective sample nested within the
Cognitive Function and Ageing Study II (CFAS-II) [17,18].
CFAS-II is a large, population-based cohort from three
geographical areas in the UK, including Newcastle upon
Tyne, measuring prevalence and incidence of dementia [18].
At baseline (2011–2013), 1,751 participants aged ≥ 65 years
were recruited to CFAS II-Newcastle sample. Global as well
as domain-specific cognitive function was assessed using the
Geriatric Mental State, the Cambridge Cognitive Examina-
tion and the Mini-Mental State Examination (MMSE). An
algorithmic approach to the diagnosis of dementia, depres-
sion and anxiety was made using the Automated Geriatric
Examination for Computer Assisted Taxonomy, drawing on
respondent and observer ratings [18]. The full content of the
interviews is available online (http://www.cfas.ac.uk/). All
members of CFAS II-Newcastle live within the catchment
area of the Newcastle Hospitals NHS Foundation Trust.
Surviving members of CFAS II-Newcastle were contacted
by CFAS prior to the start of the DECIDE study. Partici-
pants were provided with written information and given the
opportunity to opt-out of further contact. All non-objecting
members of CFAS-II Newcastle, with or without dementia,
were eligible to participate in DECIDE if admitted to the
Royal Victoria Infirmary or Freeman Hospital as an emer-
gency or electively between 5 January 2016 and 5 January
2017. We were alerted to admissions by a Recurring Admis-
sion Patient Alert on the electronic records system. If the par-
ticipant themselves lacked capacity, an appropriate personal
consultee was requested to provide written confirmation
of willingness to participate. Once recruited, participants
were seen on each subsequent hospital admission during
the study period. Participants were excluded if: they lacked
capacity to consent and we were unable to identify or contact
an appropriate personal consultee, they were receiving end
of life care, they were being isolated for infection control




Participants were assessed daily throughout their admission.
Delirium was ascertained using a standardised procedure
based on DSM-5 criteria, combining objective testing of the
participant, and information gained from informants (usu-
ally nurses, next of kin or clinical records), with structured
observations made by two assessors [19]. Disturbance in
attention was evaluated using months of the year backwards
and digit span, and arousal was recorded using the Obser-
vational Scale of Level of Arousal and the modified Rich-
mond Agitation and Sedation Scale [20–22]. Disturbance in
cognition was evaluated using 3 item recall, 10 orientation
questions, 3 stage commands and any evidence of perceptual
disturbances along with observations by the examiner during
the interview. Acute onset and fluctuating course, change from
baseline and evidence of underlying medical condition were
obtained from informant history from nursing staff, next of
kin and clinical records. In order to operationalise grades of
delirium exposure, we considered three related quantities:
(1) number of episodes; (2) total days with delirium; (3)
peak delirium severity scores recorded using the Memorial
Delirium Assessment Scale (MDAS) [22].
As far as possible, we assessed participants daily during
their hospital admission(s) for the presence of delirium. If
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any particular time point, due to illness, refusal or study
capacity, we used a validated tool to retrospectively review
the medical records for a diagnosis of delirium [23]. In those
participants in whom a diagnosis of delirium was not pos-
sible prospectively or was uncertain, study information was
sent to an expert consensus panel [LMA, DHJD, SGP]. The
vignettes contained a complete copy of the data collection
forms for the participant along with all information collected
retrospectively from the medical records using the validated
tool [23]. Two members of the expert panel [LMA, DHJD]
independently reviewed each case and if they disagreed, a
third member [SGP] reviewed the case and a majority deci-
sion was applied. The panels were tasked with determining
whether delirium was present or absent.
Illness severity
Concurrent illness severity was recorded using APACHE II
[24].
Other variables
We collected baseline data on recruitment to DECIDE
including age, sex, comorbidity (recorded using the Cumula-
tive Illness Rating Scale for Geriatrics (CIRS-G)) and frailty
(recorded using the Clinical Frailty Scale) [25,26].
Outcomes
We invited all participants recruited in hospital, with and
without delirium, for follow-up 12 months after their most
recent hospital discharge. This consisted of a home visit
to complete the CFAS II interview for dementia ascertain-
ment [18]. The primary outcomes were dementia status
and MMSE score at 12 months after hospital discharge in
comparison to baseline cognitive function from CFAS II.
Data collection
All data collection was carried out by the chief investigator
[SJR] and a part-time research nurse. At monthly intervals
throughout the study, we completed joint assessments of
a sample of participants to optimise consistency between
assessors. Training to deliver the standardised computerised
interview at 1-year follow up was provided by the CFAS team
based at University of Cambridge. They also had oversight of
on-going quality control, using audio recording of interviews
with consenting participants.
Statistical analysis
We evaluated between groups differences using an inde-
pendent t-test, Kruskall–Wallis test or chi-squared test
depending on data type and distribution. We used multiple
regression to determine whether delirium was associated
with cognitive decline or dementia, independent of baseline
cognition and illness severity along with other relevant
confounders including age, education, sex, frailty, baseline
cognition, time between baseline and follow up interviews
and comorbidities. We used multiple regressions to estimate
the effect of peak delirium severity, delirium duration and
total number of episodes of delirium. We investigated
patterns of missing data and delirium cases evaluated by
the expert panel in sensitivity analyses. All statistical analyses
were performed on STATA Version 15.
Results
Characteristics
Of the 1,751 CFAS II-Newcastle participants with baseline
data, 1,328 were surviving and non-objecting at the start of
the DECIDE study. During the year of recruitment, 363
(27·3%) were admitted to hospital, 280 were eligible for
DECIDE and 205 were recruited (73·2%) (Figure 1). There
were no significant differences in baseline characteristics
between those who were recruited to DECIDE and those
who were not (Supplementary Table 1). Baseline character-
istics of DECIDE participants are summarised in Table 1.
Ninety six of the 205 participants were readmitted during
the study period (46·8%), with a total of 186 readmissions.
Median length of stay for all admissions was 5 days (IQR
10·3 days).
Delirium
A total of 82 participants developed delirium in hospital
during the study period (40%) and 24 participants had
more than one episode of delirium (29%). For those who
experienced delirium, the median total number of days
with delirium during the study period was 3 days (IQR
6 days). Older age (OR 1·09 per year [95% CI 1·03–
1·16]) and lower baseline cognition (OR 0.95 per MMSE
point [95% CI 0·91–0.99]) were independently associated
with delirium.
Follow-up interviews at 12 months
One hundred and thirty five of 205 participants completed
follow up interviews 1 year after hospital admission (65·9%),
with 18 participants receiving a new diagnosis of dementia. A
total of 38 participants had died prior to follow up (18·5%)
and 32 refused follow up (15·6%) (Figure 1). Mean time
between participants’ baseline interview, as part of CFAS II-
Newcastle, and their follow up interview for DECIDE, was
4.5 years (SD 0.8 years).
The association between delirium and new
dementia
An episode of delirium was associated with a markedly
increased risk of incident dementia (OR 8.8 [95% CI
1.9–41.4]), independent of illness severity and baseline
cognition, as well as age, sex, education, comorbidity,
time between interviews and frailty (Table 2). Delirium
also independently predicted a decline in MMSE score at
follow up interview (β −1.8 points [95% CI –3.5 to –0.2])
(Table 3). Greater exposure to delirium, in terms of number
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Figure 1. Flowchart showing recruitment to the DECIDE study along with the proportion of participants who completed follow
up interviews at 1 year, along with the reasons for non-completion at each stage.
cognitive outcomes, with greater risk of incident dementia
associated with more than 1 episode of delirium (OR 13.9
[95% CI 1.3–151.0]) compared to a single episode (OR
8.6 [95% CI 1.8–41.1]) (Table 2). Additionally, having
delirium for more than 5 days during the study period
was independently associated with lower MMSE scores at
follow up interview (β −5.1 points [95% CI –8.1 to 2.1])
compared to 1–5 days with delirium (β −1.7 points [−3.4–
0.1]) (Table 3). More severe delirium was associated with
lower MMSE scores at follow up interview (β −0.4 points
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Table 1. Baseline characteristics of participants
Variable Total (n = 205) Delirium (n = 82) No delirium (n = 123) P value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (mean, SD) 82.0 ± 6.5 84.7 ± 6.5 80.3 ± 5.9 P < 0.001
Sex (% women) 53.2 48.8 56.1 P = 0.304
≤10 years in full time education (%) 71.2 78.1 66.7 P = 0.078
Baseline cognition (MMSE) (mean, SD) 26.3 ± 3.2 24.9 ± 3.7 27.3 ± 2.5 P < 0.001
% living in 24 h care 5.9 7.3 4.9 P = 0.466
Comorbidity score (mean, SD) 8.6 ± 4.3 10.1 ± 4.2 7.6 ± 4.1 P < 0.001
Clinical frailty score (mean, SD) 4.3 ± 1.4 4.9 ± 1.2 3.8 ± 1.4 P < 0.001
Demographic data for all DECIDE participants, those who developed delirium during the study period and those who did not develop delirium during this time.
Age, accommodation, comorbidity score (total CIRS-G score) and frailty (total Clinical Frailty Scale score) recorded on recruitment to DECIDE.
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Results of consecutive regression analyses exploring delirium variables which independently predict new dementia diagnosis at 1 year after hospital admission
(n = 135). Other variables not shown but adjusted for in regression analysis were: age (at recruitment to DECIDE), sex, education, illness severity (peak total
APACHE II score), baseline cognition (MMSE score at baseline), co-morbidity (total CIRS-G score recorded on recruitment to DECIDE), frailty (total Clinical
Frailty Score recorded on recruitment to DECIDE, included as a continuous variable) and time between baseline and follow-up interviews.
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Results of consecutive regression analyses exploring delirium variables which independently predict MMSE score at 1 year after hospital admission (n = 135). Other
variables not shown but adjusted for in regression analysis were: age (at recruitment to DECIDE), sex, education, illness severity (peak total APACHE II score),
baseline cognition (MMSE score at baseline), co-morbidity (total CIRS-G score recorded on recruitment to DECIDE), frailty (total Clinical Frailty Score recorded
on recruitment to DECIDE, included as a continuous variable) and time between baseline and follow-up interviews.
Sensitivity analyses showed that excluding the four delir-
ium cases ascertained via consensus panel requiring a third
assessor did not alter the overall results.
Discussion
In this prospective, population-based cohort study, we have
shown for the first time that delirium is associated with a new
diagnosis of dementia and cognitive decline, independent
of baseline cognition and illness severity. Further, repeated
episodes of delirium, more days with delirium and greater
severity of delirium are associated with worse cognitive out-
comes. Taken together, these findings suggest that increasing
grades of delirium exposure (in terms of recurrent episodes,
greater severity or longer duration) confer increased risk of
dementia.
A strength of DECIDE was the prospective delirium
assessments using a standardised approach, including a con-
sensus panel for borderline cases. However, not all partici-
pants were seen every day, which might not have captured all
days with delirium, particularity given the fluctuating nature
of the condition. We mitigated this using review of notes
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an existing, well-characterised cohort with known baseline
cognition was also a strength because baseline cognition
could be robustly accounted for when quantifying cognitive
outcomes after delirium. A limitation was the variation in
time that had elapsed between baseline and follow up cogni-
tive assessments. We included a term for this as a potential
confounder in our models but it is possible that cognitive
function may have deteriorated during this time.
The magnitude and direction of these independent asso-
ciations are similar to those found in previous studies in
which delirium ascertainment was retrospective. The first
used data from the original Cognitive Function and Ageing
Study cohort (CFAS I) [13], and the second used data from
a population-based study of over 85-year olds in Finland
[11]. We have not only confirmed the associations, but by
accounting for illness severity and baseline cognition and
ascertaining delirium prospectively, our results add more
detail on the interrelationship between delirium and cogni-
tive outcomes. Additionally, the relationship demonstrated
between increasing delirium exposure and cognitive decline
supports a dose–response relationship and strengthens evi-
dence for a causal hypothesis [7].
There are substantial clinical implications of this asso-
ciation between grades of delirium exposure and incident
dementia and cognitive decline because delirium itself is
modifiable, and in some cases preventable [27]. This paves
the way for future dementia prevention trials that focus on
delirium intervention in order to robustly assess whether
delirium is a modifiable risk factor for dementia. The
DECIDE study serves to emphasise that delirium may have
consequences well beyond the acute phase and may itself be
contributing to the development and burden of dementia,
significant for both individuals and populations.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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